Leap Therapeutics(LPTX) - 2025 Q2 - Quarterly Report
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 47 Thorndike St, Suite B1-1, Cambridge, MA Address of Principal Executive Offices 27-4412575 (I.R.S. Employer Identification No.) (617) 714-0360 For the transition period from ...